First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer : KEYNOTE-024 Japan subset
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association..
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE-024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a programmed death-ligand 1 (PD-L1) tumor proportion score of 50% or greater evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy (four to six cycles). The primary end-point was progression-free survival; secondary end-points included overall survival and safety. Of 305 patients randomized in KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). The hazard ratio (HR) for progression-free survival by independent central review (data cut-off date, 10 July 2017) was 0.25 (95% confidence interval [CI], 0.10-0.64; one-sided, nominal P = .001). The HR for overall survival (data cut-off date, 15 February 2019) was 0.39 (95% CI, 0.17-0.91; one-sided, nominal P = .012). Treatment-related adverse events occurred in 21/21 (100%) pembrolizumab-treated and 18/19 (95%) chemotherapy-treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 3-5 events. Immune-mediated adverse events and infusion reactions occurred in 11 patients (52%) and four patients (21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 3-5 events. Consistent with results from KEYNOTE-024 overall, first-line pembrolizumab improved progression-free survival and overall survival vs chemotherapy with manageable safety among Japanese patients with metastatic non-small-cell lung cancer without EGFR/ALK alterations and a PD-L1 tumor proportion score of 50% or greater. The trial is registered with ClinicalTrials.gov: NCT02142738.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Cancer science - 112(2021), 12 vom: 20. Dez., Seite 5000-5010 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Satouchi, Miyako [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.12.2021 Date Revised 18.12.2021 published: Print-Electronic ClinicalTrials.gov: NCT02142738 Citation Status MEDLINE |
|---|
| doi: |
10.1111/cas.15144 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330853554 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330853554 | ||
| 003 | DE-627 | ||
| 005 | 20231225212200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cas.15144 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330853554 | ||
| 035 | |a (NLM)34543477 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Satouchi, Miyako |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer |b KEYNOTE-024 Japan subset |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.12.2021 | ||
| 500 | |a Date Revised 18.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02142738 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. | ||
| 520 | |a This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE-024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a programmed death-ligand 1 (PD-L1) tumor proportion score of 50% or greater evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy (four to six cycles). The primary end-point was progression-free survival; secondary end-points included overall survival and safety. Of 305 patients randomized in KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). The hazard ratio (HR) for progression-free survival by independent central review (data cut-off date, 10 July 2017) was 0.25 (95% confidence interval [CI], 0.10-0.64; one-sided, nominal P = .001). The HR for overall survival (data cut-off date, 15 February 2019) was 0.39 (95% CI, 0.17-0.91; one-sided, nominal P = .012). Treatment-related adverse events occurred in 21/21 (100%) pembrolizumab-treated and 18/19 (95%) chemotherapy-treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 3-5 events. Immune-mediated adverse events and infusion reactions occurred in 11 patients (52%) and four patients (21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 3-5 events. Consistent with results from KEYNOTE-024 overall, first-line pembrolizumab improved progression-free survival and overall survival vs chemotherapy with manageable safety among Japanese patients with metastatic non-small-cell lung cancer without EGFR/ALK alterations and a PD-L1 tumor proportion score of 50% or greater. The trial is registered with ClinicalTrials.gov: NCT02142738 | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Japan | |
| 650 | 4 | |a PD-L1 protein | |
| 650 | 4 | |a non-small-cell lung carcinoma | |
| 650 | 4 | |a pembrolizumab | |
| 650 | 4 | |a treatment outcome | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Pemetrexed |2 NLM | |
| 650 | 7 | |a 04Q9AIZ7NO |2 NLM | |
| 650 | 7 | |a Carboplatin |2 NLM | |
| 650 | 7 | |a BG3F62OND5 |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Nosaki, Kaname |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Toshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagawa, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Aoe, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kurata, Takayasu |e verfasserin |4 aut | |
| 700 | 1 | |a Sekine, Akimasa |e verfasserin |4 aut | |
| 700 | 1 | |a Horiike, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuhara, Tatsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Sugawara, Shunichi |e verfasserin |4 aut | |
| 700 | 1 | |a Umemura, Shigeki |e verfasserin |4 aut | |
| 700 | 1 | |a Saka, Hideo |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Isamu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kishi, Kazuma |e verfasserin |4 aut | |
| 700 | 1 | |a Katakami, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Horinouchi, Hidehito |e verfasserin |4 aut | |
| 700 | 1 | |a Hida, Toyoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Atagi, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Ohira, Tatsuo |e verfasserin |4 aut | |
| 700 | 1 | |a Rong Han, Shi |e verfasserin |4 aut | |
| 700 | 1 | |a Noguchi, Kazuo |e verfasserin |4 aut | |
| 700 | 1 | |a Ebiana, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Hotta, Katsuyuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer science |d 2003 |g 112(2021), 12 vom: 20. Dez., Seite 5000-5010 |w (DE-627)NLM12479498X |x 1349-7006 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2021 |g number:12 |g day:20 |g month:12 |g pages:5000-5010 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cas.15144 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2021 |e 12 |b 20 |c 12 |h 5000-5010 | ||